Long-Term Efficacy and Safety of Once-Monthly Pasireotide in Cushing's Disease

A Phase III Extension Study

Maria Fleseriu; Stephan Petersenn; Beverly M. K. Biller; Pinar Kadioglu; Christophe De Block; Guy T'Sjoen; Marie-Christine Vantyghem; Libuse Tauchmanova; Judi Wojna; Michael Roughton; André Lacroix; John Newell-Price

Disclosures

Clin Endocrinol. 2019;91(6):776-785. 

In This Article

Conclusions

Patients who entered this extension study exhibited sustained biochemical and clinical benefit over 3 years of treatment with long-acting pasireotide, which was accompanied by improvements in QoL and tumour size control. The long-term safety profile of pasireotide was favourable and consistent with that reported during the first 12 months of treatment. These data support the use of long-acting pasireotide as an effective long-term treatment option for some patients with CD.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....